NPC(SH:600713)2025-10-30 08:05Financial Performance - The company's operating revenue for the third quarter was CNY 13,167,730,186.85, a decrease of 3.93% compared to the same period last year[5] - The total profit for the quarter was CNY 181,692,169.91, down 18.04% year-on-year[5] - The net profit attributable to shareholders was CNY 110,694,512.43, reflecting a decline of 15.22% compared to the previous year[5] - The basic earnings per share decreased by 10.00% to CNY 0.09, while diluted earnings per share fell by 20.00% to CNY 0.08[5] - Total operating revenue for the first three quarters of 2025 reached ¥41.14 billion, a slight increase of 0.48% compared to ¥40.94 billion in the same period of 2024[38] - Net profit for the first three quarters of 2025 was ¥529.76 million, down 6.04% from ¥563.81 million in the previous year[39] - The total comprehensive income for the first three quarters of 2025 was ¥527.35 million, down from ¥591.96 million in 2024, reflecting a decline of 10.87%[39] - The net profit for the first three quarters of 2025 was CNY 336,047,245.31, down 8.0% from CNY 365,157,231.84 in the first three quarters of 2024[45] Assets and Liabilities - Total assets increased by 10.99% to CNY 34,045,054,183.45 compared to the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to RMB 34,045,054,183.45, an increase from RMB 30,673,626,932.52 as of December 31, 2024[34] - Current assets totaled RMB 31,003,426,359.15, compared to RMB 27,807,861,740.60 at the end of 2024, reflecting a growth of approximately 11.5%[35] - The total liabilities and shareholders' equity reached ¥34.05 billion, an increase of 10.00% from ¥30.67 billion in the previous year[38] - The total liabilities increased to CNY 13,892,435,691.26 as of September 30, 2025, compared to CNY 12,444,743,701.74 at the end of 2024[43] Cash Flow - Cash flow from operating activities showed a significant decline, primarily due to reduced sales collections[8] - The net cash flow from operating activities for the first three quarters of 2025 was -¥4.98 billion, worsening from -¥2.89 billion in the same period of 2024[41] - The company's cash flow from operating activities showed a net outflow of CNY 1,705,552,524.18 for the first three quarters of 2025, compared to a net outflow of CNY 1,101,127,686.26 in the same period of 2024[46] - The net cash flow from investing activities was -$2.08 billion, compared to -$1.53 billion in the previous period[47] - The net cash flow from financing activities was $2.45 billion, up from $1.62 billion in the prior period[47] - The company experienced a net decrease in cash and cash equivalents of -$1.34 billion, compared to -$1.01 billion in the previous period[47] Shareholder Information - The company reported a total of 51,638 common shareholders at the end of the reporting period[10] - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., holds 44.17% of the shares[10] - The company repurchased 17,999,852 shares, accounting for 1.38% of the total share capital, with a total expenditure of RMB 88,922,100[17] Investments and Financing - The company issued 10,814,910 convertible bonds with a total fundraising amount of RMB 1,081,491,000, net amount after expenses being RMB 1,069,040,922.31[13] - The company issued short-term financing bonds totaling RMB 15 billion to supplement working capital and repay bank loans[19] - The company approved a borrowing limit of up to RMB 4 billion from its controlling shareholder for daily operational funding[24] - The company signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group, where Baiyunshan's subsidiary plans to acquire 144,557,431 shares from Alliance Healthcare, representing 11.04% of the company's total shares[27] Research and Development - Research and development expenses decreased to ¥25.90 million in 2025 from ¥30.54 million in 2024, indicating a reduction of 15.36%[38] - The company reported a decrease in research and development expenses to CNY 7,576,143.84 in the first three quarters of 2025, down from CNY 8,818,792.19 in the same period of 2024[44] Other Information - The company completed the purchase of its headquarters building for a total price of RMB 326,736,120.00[29] - The company held a half-year performance briefing on September 18, 2025, to address investor concerns and provide updates on its financial performance[32] - The company appointed several new vice presidents, aligning their terms with the current board's tenure[33] - The company will not apply new accounting standards starting from 2025[48]